OS THERAPIES INCORPORATED APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
OS THERAPIES INCORPORATED (OSTX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $1.33M, a 47.05% increase year-over-year.
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $1.44M, a 52.49% increase year-over-year.
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $814.93K.
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $905.18K.
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $4.27M, a 1489.78% increase from fiscal 2024.
- OS THERAPIES INCORPORATED apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $268.30K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.33M 10-Q · filed 2026-08-14 | $2.77M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $1.44M 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $4.27M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $814.93K 10-Q · filed 2025-11-14 | $1.72M derived: sum of 2 quarters · filed 2026-08-14 | $2.66M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $905.18K 10-Q · filed 2026-08-14 | $1.85M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $941.28K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $268.30K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |